Avinger-lumivascular-hero-mobile Avinger-lumivascular-hero-tablet
homepage_hero4_why_lumivascular

Combining real time intravascular imaging with therapeutic devices to
avoid damaging the native artery

VISUALIZATION.

Knowledge is power. The ability to see inside the artery during treatment gives physicians a lot more knowledge of the clinical problem and the power to do something about it in real time.

img-lumi-visual
  • ADVENTITIA

    The supportive and outermost layer of the artery is also the most sensitive to injury during treatment.

  • External Elastic Lamina (EEL)

    Science has proven that when this thin bright border is breached, the body may generate an aggressive healing response that leads to renarrowing of the artery.

  • Media

    The middle or muscular layer of the artery shows up as a dark band with OCT imaging.

  • PLAQUE

    The deposits that cause the narrowing in the artery can easily be characterized and differentiated from the arteries natural structures because it’s non layered and amorphous.

PRECISION.

Our Lumivascular technology has generated some of the most compelling data in our industry to date – proving that being able to see and treat at the same time can provide best in class clinical outcomes.

vision ide trial – lumivascular ATHERECTOMY

VISION IDE was a non randomized, single arm clinical study to evaluate the safety and effectiveness of Pantheris.

TLR 6 Months

8%
6 month target lesion revascularization (TLR by patient)

Dissections

Dissections

Perforations

Perforations

Percent Stenosis

  • 79%
    Pre-stenosis
  • 30%
    PANTHERIS STANDALONE
  • 22%
    PANTHERIS +/- adjunctive therapy

Connect II ide trial – Lumivascular CTO CROSSING

CONNECT II was a non randomized, single arm clinical study to evaluate the safety and effectiveness of Ocelot.

Luminal Crossing

93%
7 %
intraluminal SUBINTiMAL
  • Efficacy

  • Perforations

Lumivascular Product Family